Objectives: Data mining algorithms have been developed for the quantitative detection of drug-associated adverse events (signals) from a large database on spontaneously reported adverse events. In the present study, the commonality of signals detected by 4 commonly used data mining algorithms was examined. Methods: A total of 2,231,029 reports were retrieved from the public release of the US Food and Drug Administration Adverse Event Reporting System database between 2004 and 2009. The deletion of duplicated submissions and revision of arbitrary drug names resulted in a reduction in the number of reports to 1,644,220. Associations with adverse events were analyzed for 16 unrelated drugs, using the proportional reporting ratio (PRR), reporting odds ratio (ROR), information component (IC), and empirical Bayes geometric mean (EBGM). Results: All EBGM-based signals were included in the PRR-based signals as well as IC-or ROR-based ones, and PRR-and IC-based signals were included in ROR-based ones. The PRR scores of PRR-based signals were significantly larger for 15 of 16 drugs when adverse events were also detected as signals by the EBGM method, as were the IC scores of IC-based signals for all drugs; however, no such effect was observed in the ROR scores of ROR-based signals.
Introduction
The US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS, formerly AERS) is a database that contains information on adverse event and medication error reports submitted to the FDA [1] [2] [3] . Besides those from manufacturers, reports can be submitted from health care professionals and the general public. The FAERS structure adheres to the International Safety Reporting Guidance issued by the International Conference on Harmonisation, ICH E2B, and adverse events are coded to terms in the
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Medical Dictionary for Regulatory Activities (MedDRA) terminology [4] . The original system was initiated in 1969; however, reporting markedly increased following the last major revision in 1997 [5, 6] . To date, the FAERS contains more than 4 million reports and is the largest repository of spontaneously reported adverse events in the world [5, 6] . The FDA releases data to the general public, and this has allowed us to conduct pharmacoepidemiological studies and/or pharmacovigilance analyses.
Data mining algorithms have been developed for the quantitative detection of signals [7] [8] [9] [10] [11] . A signal indicates an association between a drug and an adverse event or drug-associated adverse event, including the proportional reporting ratio (PRR) [12] , reporting odds ratio (ROR) [13] , information component (IC) given by a Bayesian confidence propagation neural network [14] , and empirical Bayes geometric mean (EBGM) [15] . Associations with adverse events of interests were previously analyzed for 16 drugs using reports in the FAERS database between 2004 and 2009 [16] [17] [18] [19] [20] [21] [22] . Whether an adverse event is detected as a signal has been shown to depend on the algorithms; however, of the 4 methods, the ROR method provided the highest number of signals, while the EBGM method provided the lowest [23] . In the present study, the commonality of PRR-, ROR-, IC-, and EBGM-based signals was examined.
Methods
Data were retrieved from the public release of the FAERS database from the first quarter of 2004 through to the end of 2009. The total number of reports obtained was 2,231,029. Duplicated reports were deleted and arbitrary drug names were revised, resulting in a reduction in the number of reports from 2,231,029 to 1,644,220. Signal scores, i.e., the PRR, ROR, IC, and EBGM values, were calculated for 16 unrelated drugs to assess associations with adverse events, including 2 antimicrobials (colistin and tigecycline), 4 HMG-CoA reductase inhibitors (statins) (pravastatin, simvastatin, atorvastatin, and rosuvastatin), 2 proton pump inhibitors (PPIs) (omeprazole and esomeprazole), warfarin, 2 antiplatelets (aspirin and clopidogrel), and 5 anticancer agents (cisplatin, carboplatin, oxaliplatin, 5-fluorouracil, and capecitabine). It is noted that the associations of these drugs with adverse events have already been published [16] [17] [18] [19] [20] [21] [22] . All values reported are the mean±standard deviation (SD). The unpaired Student's t-test/Welch's test or Mann-Whitney's U test was used for two-group comparisons of the values. P values of less than 0.05 were considered significant. Figure 1 shows the relationship among the PRR-, ROR-, IC-, and EBGM-based signals, which was commonly observed for all 16 drugs. All EBGM-based signals were included in the PRR-based signals as well as IC-or ROR-based ones. The PRR-and IC-based signals were included in the ROR-based ones. Therefore, ROR-based signals could be stratified into 5 groups; signals detected by the ROR only, signals detected by the ROR and PRR, signals detected by the ROR and IC, signals detected by the ROR, PRR, and IC, and signals detected by the 4 methods. Table 1 lists the numbers of signals in the 5 groups. The ratio of the total number of EBGM-based signals to that of signals detected by the ROR only varied from 3.9% with omeprazole to 57.3% with oxaliplatin. The ratio of the total number of EBGM-based signals to that of ROR-based signals varied from 1.7% with omeprazole to 20.5% with oxaliplatin. Table 2 lists the PRR scores of PRR-based signals. Since PRR-based signals could be divided into 2 groups based on whether adverse events were also detected as signals by the EBGM method (Figure 1 ), the effects of additional detection by the EBGM method on PRR scores was examined. As shown in Table 2 , the scores were significantly larger for 15 of 16 drugs when adverse events were also detected as signals by the EBGM method. Tables 3 and 4 show data on the ROR and IC, respectively. The effects of additional detection by the EBGM method found for PRR scores were not observed for the ROR, whereas the IC scores of IC-based signals were the same as the PRR scores of PRR-based signals. Cisplatin  356  98  49  206  175  Carboplatin  321  77  80  188  144  Oxaliplatin  262  64  60  196  150  Colistin  166  18  1  30  23  5-Fluorouracil  341  82  62  218  161  Capecitabine  340  67  51  198  146  Pravastatin  358  58  125  141  19  Simvastatin  284  61  268  101  30  Atorvastatin  304  65  295  164  55  Rosuvastatin  295  42  97  122  63  Tigecycline  155  18  2  29 PRR-based signals were divided into 2 groups based on whether adverse events were also detected by the EBGM method. IC-based signals were divided into 2 groups based on whether adverse events were also detected by the EBGM method.
Results
Discussion
Several studies previously compared data mining algorithms [13, [24] [25] [26] [27] [28] [29] ; however, as Bate and Evans recently concluded [7] , different algorithms have slightly different properties such that one may consequently be preferable in a particular application. If used for pharmacovigilance, data mining algorithms should be assessed from the standpoint of early and timely signal detection [30] [31] [32] [33] . Although few studies have published comparative data, Chen et al. recently compared the timing of early signal detection with PRR, ROR, IC, and EBGM using the FAERS database, and concluded that the ROR performed better [30] . We previously reported that the ROR method provided the highest number of signals, while the EBGM method provided the lowest [23] . The difference in the number of signals can be attributed to a higher rate of false positives or lower ability to detect signals. In the present study, the commonality of signals was clarified, as shown in Figure 1 . The EBGM method was shown to be the most conservative among the 4 methods, which suggested that it was suitable for pharmacoepidemiological studies. In contrast, the ROR method was shown to be the most comprehensive, indicating its usefulness for pharmacovigilance. These results were consistent with the findings of Chen et al [30] . These 4 data mining algorithms were used in our previous studies [16] [17] [18] [19] [20] [21] [22] , and adverse events were listed as drug-associated, when at least 1 of the 4 indices met the criteria. However, the results shown in Figure 1 demonstrated that lists of adverse events were only identical when the ROR method was applied, which suggested that care should be taken in interpreting data when signals are not detected by the EBGM method.
Based on the number of signals, 16 drugs could be classified into 4 groups. Group 1 included 2 antimicrobials, which were characterized by the lower number of signals. The total number of co-occurrences with colistin was only 1,491, and 1,906 for tigecycline. These were markedly less than those of the other 14 drugs; from 33,197 with oxaliplatin to 220,194 with atorvastatin. The lower number of signals can be explained by comparatively infrequent use, and, therefore, a smaller number of reports in the database. This is not related to the reliability of the signals.
Group 2 included 4 statins and 2 PPIs characterized by a lower number of EBGM-based signals, and group 3 included warfarin and 2 antiplatelets by a higher number of EBGM-based signals. Group 4 included 5 anticancer agents characterized by a much higher number of EBGM-based signals. The total number of ROR-based signals was similar among drugs in groups 2-4; from 619 with rosuvastatin to 884 with cisplatin. The ROR method is feasible for detecting more signals, including false positives, than the EBGM method. The difference observed in the ratio of EBGM-based to ROR-based signals may reflect whether adverse events are generally found.
A pilot study performed by Hochberg et al. in 2009 concerning drug-versus-drug comparisons revealed that the rank-order of adverse event rates in the FAERS database was consistent with the results of published studies [34] , which encouraged the use of the database for comparisons. In other investigations, the number of reports with or without normalization by usage or sales during the corresponding period was used to compare drugs [35] ; however, adverse events are underreported, which may lead to incorrect conclusions [36] [37] [38] . Signal scores have also been considered inappropriate for determining the rank-order of drugs in terms of risk; however, few studies have been published to date. In the present study, the EBGM method was shown to be the most conserva-tive among the 4 methods; therefore, it is important to confirm whether this method can provide important information similar to that in well-organized clinical studies.
